Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Overview

How likely is it that the drugs in Hypersensitivity will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Hypersensitivity Overview

Hypersensitivity reactions (HR) are exaggerated immune responses categorized by Coombs and Gell. Immediate hypersensitivity reactions (IHR) include Type I, II, and III hypersensitivity reactions, mediated by antibodies such as IgE, IgM, and IgG. Type I involves IgE-mediated anaphylactic responses, seen in conditions like bronchial asthma, allergic rhinitis, and anaphylaxis. Type II involves cytotoxic-mediated responses mediated by IgG and IgM, leading to diseases like immune thrombocytopenia and autoimmune hemolytic anemia. Type III includes immunocomplex reactions, as seen in serum sickness and Arthus reaction, mediated by IgM and IgG antibodies. These reactions activate the complement system, causing inflammation and tissue damage.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Reasons to buy

  • Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
  • Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
  • Use PTSR and LOA information and event-driven changes for your investment decisions.

What our clients have to say

More Reports

View More Reports